2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Omics Technologies, Pathology, Serologic Tests, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

2216 IVIG and infection-free survival after BCMA bispecific therapy in multiple myeloma

Baqir Hasan Jafry, MD, Haris Sohail, MD, MBBS2, Jennifer Elizabeth Collins, PhD3, Amir Kamran, MD4
1 Charleston Area Medical Center, Charleston, United States
2 Charleston Area Medical Center, Charleston, United States
3 Charleston Area Medical Center, Charleston, United States
4 Charleston Area Medical Center, Charleston, United States

Background: BCMA-directed bispecific antibodies are increasingly used for relapsed/refractory multiple myeloma (RRMM), but infections remain a major cause of morbidity and may limit safe delivery of therapy. Intravenous immunoglobulin (IVIG) is used as supportive care in selected patients, but real-world evidence defining its impact after BCMA bispecific initiation remains limited. We evaluated whether early IVIG use was associated with improved infectious outcomes among patients receiving teclistamab or elranatamab.

Methods: We performed a retrospective cohort study using the TriNetX Research Network. Adults with multiple myeloma receiving teclistamab or elranatamab after prior myeloma-directed therapy were included; RRMM was approximated by prior anti-myeloma treatment before bispecific initiation. Early IVIG was defined as IVIG use within 60 days after bispecific initiation. To reduce immortal time bias, the primary analysis used a 60-day landmark design, with outcomes assessed from day 60 through day 180. Patients receiving early IVIG were propensity score matched 1:1 to patients not receiving early IVIG for age, sex, race, ethnicity, comorbidities, prior CAR-T therapy, prior infections and hospitalizations, hypogammaglobulinemia, neutropenia, prior myeloma therapies, corticosteroid exposure, antimicrobial use, and G-CSF use. The primary outcome was infection-free survival. Secondary outcomes included infection subtypes, hospitalization, critical care services utilization, and mortality.

Results: Before matching, 416 patients were identified in the early IVIG cohort and 959 in the non-IVIG cohort. After matching, 359 patients remained in each group. In the primary 60–180 day landmark analysis, early IVIG use was associated with significantly higher infection-free survival compared with no early IVIG use (72.7% vs 60.6%; HR 0.66, 95% CI 0.50–0.86; p=0.002). Sepsis occurred less frequently in the IVIG cohort (5.0% vs 11.7%; RR 0.43, 95% CI 0.25–0.73; p=0.001), as did mortality (6.6% vs 12.1%; RR 0.55, 95% CI 0.33–0.90; p=0.016). Bacteremia was numerically lower with IVIG but did not reach statistical significance (3.1% vs 5.9%; RR 0.52, 95% CI 0.26–1.07; p=0.071). Any infection was also lower in the IVIG cohort, although not statistically significant in the landmark window (22.3% vs 26.7%; RR 0.83, 95% CI 0.64–1.08; p=0.165). Rates of pneumonia (11.7% vs 13.4%; RR 0.88; p=0.499), viral infection (6.7% vs 8.9%; RR 0.75; p=0.266), fungal infection (6.1% vs 5.3%; RR 1.16; p=0.630), opportunistic infection (6.4% vs 7.8%; RR 0.82; p=0.468), hospitalization (20.9% vs 20.3%; RR 1.03; p=0.854), and critical care services utilization (5.3% vs 6.7%; RR 0.79; p=0.432) were not significantly different.

Exploratory analyses from bispecific initiation showed consistent improvement in infection-free survival with IVIG at 30 days (83.0% vs 75.3%; HR 0.65, 95% CI 0.47–0.91; p=0.010), 90 days (67.3% vs 54.1%; HR 0.65, 95% CI 0.51–0.82; p<0.001), and 180 days (57.3% vs 40.2%; HR 0.63, 95% CI 0.51–0.77; p<0.001). At 180 days, IVIG use was also associated with lower rates of any infection (37.9% vs 45.7%; RR 0.83, 95% CI 0.70–0.99; p=0.034), mortality (12.6% vs 24.9%; RR 0.51, 95% CI 0.37–0.70; p<0.001), and lower critical care services utilization with borderline statistical significance (9.5% vs 14.2%; RR 0.67, 95% CI 0.44–1.00; p=0.050).

Conclusion: In this multicenter propensity score-matched landmark analysis of patients with RRMM receiving BCMA-directed bispecific antibodies, early IVIG use was associated with improved infection-free survival and lower rates of sepsis and mortality. These findings support IVIG as a potentially important supportive-care strategy for patients receiving BCMA bispecific therapy and warrant prospective evaluation of optimal timing, duration, and patient selection.

Baqir Hasan Jafry, MD: No relevant conflicts of interest to declare.